1
|
Zeng D, Zhao X, Di L, Lou L, Song Y, Zhang Y, Liu H, Li G. Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report. Front Oncol 2022; 12:918297. [PMID: 35875132 PMCID: PMC9300950 DOI: 10.3389/fonc.2022.918297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 06/13/2022] [Indexed: 11/13/2022] Open
Abstract
The identification of ERBB2 (HER2) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of ERBB2 mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-year-old female diagnosed with hCCA complicated by liver metastases after radical resection. The next-generation sequencing assay showed that the tumor had an ERBB2 mutation. Then, the patient was treated with trastuzumab plus capecitabine. After 2 months of treatment, she had a partial response. Until now, the patient is still alive. This study has shown the potential of trastuzumab combined with capecitabine as an effective treatment for hilar cholangiocarcinoma complicated by liver metastases harboring ERBB2 alterations.
Collapse
Affiliation(s)
- Daobing Zeng
- General Surgery Department, Beijing Youan Hospital, Capital Medical University, Beijing, China
- Clinical Center for Liver Cancer, Capital Medical University, Beijing, China
| | - Xiaofei Zhao
- General Surgery Department, Beijing Youan Hospital, Capital Medical University, Beijing, China
- Clinical Center for Liver Cancer, Capital Medical University, Beijing, China
| | - Liang Di
- General Surgery Department, Beijing Youan Hospital, Capital Medical University, Beijing, China
- Clinical Center for Liver Cancer, Capital Medical University, Beijing, China
| | - Luyan Lou
- Medical Affairs Department, Acornmed Biotechnology Co. Ltd., Beijing, China
| | - Yanfang Song
- Medical Affairs Department, Acornmed Biotechnology Co. Ltd., Beijing, China
| | - Yanrui Zhang
- Medical Affairs Department, Acornmed Biotechnology Co. Ltd., Beijing, China
| | - Huanhuan Liu
- Medical Affairs Department, Acornmed Biotechnology Co. Ltd., Beijing, China
| | - Guangming Li
- General Surgery Department, Beijing Youan Hospital, Capital Medical University, Beijing, China
- Clinical Center for Liver Cancer, Capital Medical University, Beijing, China
- *Correspondence: Guangming Li,
| |
Collapse
|
2
|
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. J Clin Med 2020; 9:jcm9072255. [PMID: 32708604 PMCID: PMC7408920 DOI: 10.3390/jcm9072255] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/09/2020] [Accepted: 07/15/2020] [Indexed: 12/19/2022] Open
Abstract
The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.
Collapse
|
3
|
Zhang W, Shi J, Li R, Han Z, Li L, Li G, Yang B, Yin Q, Wang Y, Ke Y, Li Q. Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation. Oncologist 2020; 25:375-379. [PMID: 32045060 DOI: 10.1634/theoncologist.2019-0498] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Accepted: 01/07/2020] [Indexed: 12/26/2022] Open
Abstract
Here, we report a case of postoperative recurrence of gallbladder carcinoma (GBC) in a patient who declined systemic chemotherapy. ATM S1905Ifs*25 and STK11 K262Sfs*25 mutations were detected by next-generation sequencing. Oral administration of olaparib was initiated. One month later, the patient experienced relief of clinical symptoms, a decrease in CA19-9 level, and a reduction in abnormal signal in the subcapsular region. The tumor response remained stable for approximately 13 months. This is the first case to demonstrate the clinical benefits of olaparib treatment in a patient with GBC harboring an ATM-inactivating mutation. This observation helps to better inform treatment options to enhance the care of patients with advanced GBC. KEY POINTS: A patient with gallbladder carcinoma harboring an ATM-inactivating mutation responded to olaparib with a progression-free survival of 13 months. This is the first report that demonstrates the clinical benefits of olaparib treatment in a patient with gallbladder carcinoma with an ATM-inactivating mutation. It also highlights the importance of next-generation sequencing, which can provide valuable information for planning effective targeted therapies for gallbladder carcinoma. Evidence-based decisions help determine the best choice of treatment for individualized patient care.
Collapse
Affiliation(s)
- Wei Zhang
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
- National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China
| | - Junping Shi
- OrigiMed, Shanghai, People's Republic of China
| | - Rentao Li
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Zhiqiang Han
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Ling Li
- OrigiMed, Shanghai, People's Republic of China
| | - Guanghao Li
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Bo Yang
- Department of Pathology and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Qiang Yin
- Department of Neurosurgery and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Yingying Wang
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Yan Ke
- Department of Pathology and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Qiang Li
- Department of Hepatobiliary Cancer and Neuro-Oncology Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| |
Collapse
|